Evidence map›Paper›PMID 34347183›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

Evaluation of a new online cognitive assessment tool in breast cancer survivors with cognitive impairment: a prospective cohort study.

Anne Bellens, Ella Roelant, Bernard Sabbe, Marc Peeters, Peter A van Dam

Abstract readReview
PubMed Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Cognitive and mental health trajectories of COVID-19: Role of hospitalisation and long-COVID symptoms.European psychiatry : the journal of the Association of European Psychiatrists · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anne BellensMultidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, B2650, Edegem, Belgium.
Ella RoelantClinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, B2650, Edegem, Belgium.
Bernard SabbeDepartment of Psychiatry, Antwerp University, Wilrijk, Belgium.
Marc PeetersMultidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, B2650, Edegem, Belgium.
Peter A van DamMultidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, B2650, Edegem, Belgium. peter.vandam@uza.be.ORCID http://orcid.org/0000-0002-9184-7703

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCurrently cancer-related cognitive impairment (CRCI) is mainly assessed by means of questionnaires, which is very laborious for the patients and the supervising physician. We evaluated a new online cognitive assessment tool, the MyCognition Quotient (MyCQ, Cambridge) in breast cancer survivors with CRCI, and compared the results with a psychometric test measuring cognitive complaints, depression, and anxiety. MATERIALS AND

methodsIn this prospective study, 46 adult patients between 18 and 70 years old with a diagnosis of BC were studied, all complaining of disturbing cognitive impairment. They participated in a physical cognitive rehabilitation program. The patients had an online cognitive assessment (MyCQ Med by MyCognition) every 4 weeks on their home computer. In addition patients were assessed in the outpatient clinic by the principal investigator at baseline, after 3 and 6 months using the following validated neuro-psychological surveys: the Hospital Anxiety and Depression Scale (HADS), Beck Cognitive Insight Scale (BCIS), and Cognitive Failure Questionnaire (CFQ). MyCQ scores were correlated with the results of these surveys.

resultsOnly weak correlations could be found between overall MyCQ or the MyCQ subtests with the psychometric tests (between - 0.43 and 0.458) at baseline and when combining data at time point 0, 3, and 6 months. Linear mixed models showed there was a significant association between Latency Choice Reaction Time and CFQ (continuous; p = 0.026). An AUC of 0.640 and a cut-off of 481.5 ms in Latency Choice Reaction Time were found to distinguish patients with CFQ below 44 to patients with CFQ above 44 (sensitivity 0.63 and specificity 0.73). In Latency Coding an AUC of 0.788 and a cut-off of 1316 ms were found to distinguish non-depressive patients from patients likely to present with depressive symptoms (sensitivity 0.75 and specificity 0.76).

conclusionMyCQ cannot replace the various psychometric tests. However, abnormal Latency in cognitive tests, Choice Reaction Time and Coding, seems promising to be used as a screening tool to detect specific aspects of abnormal cognitive functioning in patients with cognitive complaints and depressive symptoms.

Indexed as

Breast NeoplasmsCancer SurvivorsCognitive DysfunctionAdolescentAdultAgedCognitionDepressionFemaleHumansMiddle AgedProspective StudiesSurveys and QuestionnairesYoung AdultBreast cancerCognitionCognitive impairmentCognitive trainingVideo gaming

Identifiers

PMID34347183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.